Assessment of intraocular pressure changes following intravitreal injections of three anti-VEGF agents
AJO International · 2024
DOI: 10.1016/j.ajoint.2024.100001 ↗Kurz gefasst
Fachartikel in der Zeitschrift AJO International, 2024. Verfasst von Amit Hibsh und 4 weiteren Autor:innen. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Intravitreal injection (IVI) of anti-vascular endothelial growth factor (anti-VEGF) agents has emerged as the primary treatment for prevalent retinal diseases. Despite its efficacy, IVI may induce intraocular pressure elevation due to vitreous fluid shifts. This study aims to compare the effects of three distinct anti-VEGF agents on intraocular pressure (IOP) elevation within a single clinic setting. A prospective study, conducted at a single retinal clinic in a tertiary medical center (Tel Aviv Sourasky Medical Centre, Tel-Aviv, Israel). Patients receiving 3 different anti VEGF medications; bevacizumab, aflibercept, and ranibizumab, were examined. IOP was measured pre- and post-injection using an iCare Pro tonometer. Demographic parameters and ocular characteristics were collected. The study included 195 patients (average age 76.13 years; 100 males, 95 females). The medications administered were aflibercept (N=70, 35%), bevacizumab (N=73, 37.4%), and ranibizumab (N=52, 26.7%). In patients with a normal baseline intraocular pressure, no significant variance was observed in the post-injection versus pre-injection pressure change (delta) across medications. Conversely, in patients with higher pressure (>20 mmHg), aflibercept incited a more substantial increase than bevacizumab or ranibizumab. No correlation emerged between the pressure rise and age or lens status. No significant difference was found in the increase of intraocular pressure following injection among different medications in patients with low-normal intraocular pressure. However, for patients prone to higher baseline pressure, caution is recommended with aflibercept due to a more pronounced increase. Further research is essential to comprehend the factors influencing pressure increase and their associated clinical implications.
Zitieren
APA
Hibsh, A., Barak, A., Fleissig, E., Regenbogen, M., & Klein, A. (2024). Assessment of intraocular pressure changes following intravitreal injections of three anti-VEGF agents. AJO International. https://doi.org/10.1016/j.ajoint.2024.100001
Vancouver
Hibsh A, Barak A, Fleissig E, Regenbogen M, Klein A. Assessment of intraocular pressure changes following intravitreal injections of three anti-VEGF agents. AJO International. 2024. doi:10.1016/j.ajoint.2024.100001
BibTeX
@article{Hibsh2024,
author = {Hibsh, Amit and Barak, Adiel and Fleissig, Efrat and Regenbogen, Michael and Klein, Ainat},
title = {Assessment of intraocular pressure changes following intravitreal injections of three anti-VEGF agents},
journal = {AJO International},
year = {2024},
doi = {10.1016/j.ajoint.2024.100001}
}
EUVIMED